Abel Jarell, MD, FAAD: Identifying the Risk of Central Nervous System Metastasis Using the 31-Gene Expression Profile Test

September 11, 2025

Dr. Abel Jarell reviews findings from a poster on the 31-GEP test’s role in identifying CNS metastasis risk in patients with stage I–II cutaneous melanoma.

Abel Jarell, MD, FAAD: Identifying the Risk of Central Nervous System Metastasis Using the 31-Gene Expression Profile Test

MORE EXPERT PERSPECTIVES IN MELANOMA:

Jason Rizzo, MD, PhD: Evaluating Melanoma-specific Survival Stratification and Survival Benefit of Gene Testing in Patients with Melanoma

Brent Moody, MD: Assessing the Prognostic Significance of the 31-gene Expression Profile Test

Jason Rizzo, MD: Utility of Gene Expression Profile Testing for Prognosis in Cutaneous Melanoma

Hadas Skupsky, MD, FAAD: Pigmented Lesion Management for the Dermatologist